Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal.
Early reports from immunotherapy trials conclude durable responses. Long-term data may indicate otherwise. Better delineation of clinical courses of long-term survivors will accelerate the discovery and application of biomarkers. Two pressing issues among those treated with anti-PD-1/PD-L1 are understanding whether responders can have therapy abbreviated and overcoming resistance in nonresponders.See related article by Gauci et al., p. 946.